Medtronic PLC $MDT is Cambiar Investors LLC's 7th Largest Position

Key Points

• Cambiar Investors LLC trimmed its Medtronic stake by 2.4% in Q4 to 575,189 shares (worth $55,253,000), making MDT ~2.5% of its portfolio and its 7th-largest holding.
• EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 at an average $97.71 for about $5.13M, reducing his ownership by 61.58%; company insiders now own 0.26% of Medtronic.
• Analysts show a Moderate Buy consensus with an average price target of $109; Medtronic set FY2026 EPS guidance of 5.620–5.660 and declared a $0.71 quarterly dividend (3.3% yield).

Cambiar Investors LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 2.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 575,189 shares of the medical technology company's stock after selling 14,226 shares during the quarter. Medtronic accounts for approximately 2.5% of Cambiar Investors LLC's portfolio, making the stock its 7th largest position. Cambiar Investors LLC's holdings in Medtronic were worth $55,253,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. State Street Corp grew its holdings in shares of Medtronic by 1.0% during the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company's stock worth $5,800,550,000 after purchasing an additional 625,992 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Medtronic by 0.9% during the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company's stock worth $2,044,637,000 after purchasing an additional 192,410 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Medtronic by 0.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company's stock worth $2,008,278,000 after purchasing an additional 98,220 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of Medtronic by 3.0% during the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company's stock worth $1,067,055,000 after purchasing an additional 327,899 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock worth $970,456,000 after buying an additional 2,658,981 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on MDT shares. Mizuho raised Medtronic to a "strong-buy" rating in a research note on Wednesday, February 18th. Argus cut their target price on Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a research note on Monday, April 6th. Barclays upped their target price on Medtronic from $118.00 to $120.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Finally, CICC Research started coverage on Medtronic in a research note on Friday, January 30th. They issued an "outperform" rating for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, Medtronic presently has an average rating of "Moderate Buy" and an average price target of $109.00.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.26% of the company's stock.

Medtronic Stock Down 0.8%

Shares of MDT opened at $87.17 on Friday. The firm has a market cap of $111.91 billion, a P/E ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.75. Medtronic PLC has a 1 year low of $79.93 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock has a 50 day simple moving average of $93.08 and a two-hundred day simple moving average of $95.97.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic's dividend payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.